Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
TOTEC Pharma is developing an Rx-strength topical cream formulation of cannabidiol (CBD) specifically for the treatment of radiation dermatitis in cancer patients. The product utilizes a dual-technology delivery system consisting of nano-structured lipid carriers (NLCs) and a patented water-based micellar system designed to enhance the solubility and penetration of CBD through the stratum corneum. By targeting Cannabinoid receptor 2 (CB2), the formulation aims to reduce inflammation, pain, and tissue damage caused by radiation therapy. The drug is currently in preclinical development, with in vivo studies demonstrating improvements in dermatitis scoring and redness.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on cannabidiol (TOTEC Pharma).